| abstract |
The present disclosure relates to antibodies and proteins comprising antigen-binding portions thereof that specifically bind the proinflammatory cytokine IL-17A. The present disclosure more particularly relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activity of IL-17A and IL-17AF) and are capable of inhibiting IL-17A-induced cytokine production in an in vitro assay , and has inhibitory effects in an antigen-induced arthritis model in vivo. The present disclosure also relates to compositions and methods of using the antibodies and proteins for the treatment of pathological disorders, such as rheumatoid arthritis, psoriasis, Systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis and other autoimmune and inflammatory disorders. |